AstraZeneca's stock has gained 31.43% over the past year, with a recent price target increase by Guggenheim to 16,500 GBp from 16,000 GBp, reflecting confidence in the company's growth. The upgrade follows strong 2025 revenue of $58.74 billion and management's guidance for continued revenue and earnings growth in 2026. Key growth drivers include a robust oncology portfolio, a deep pipeline with multiple Phase 3 trials and approvals, and increased capital investment, including a $15 billion China expansion. To reach the new target, AstraZeneca must sustain growth and capitalize on its pipeline, though risks include potential pipeline setbacks and currency fluctuations.
AstraZeneca PLC will announce its Q2 2026 earnings on July 27, following a strong Q1 with 12.5% revenue growth to $15.29 billion. Key growth driver Enhertu saw a 39.4% year-over-year revenue increase, reaching $831 million, and recently gained EU app...
AstraZeneca has agreed to pay $600 million upfront and up to $1.5 billion total for global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer with a specific genetic mutation ...
AstraZeneca has agreed to pay $600 million upfront, with up to $900 million more based on milestones, to acquire global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer pati...
HSBC downgraded AstraZeneca from 'buy' to 'hold' following the failure of its Wainua phase III trial for a heart disease treatment, which missed its primary endpoint. This trial was a major part of HSBC's positive outlook, and its failure has led to ...
UBS maintains a 'buy' rating on AstraZeneca ahead of its Q2 results due on July 27, expecting solid performance but no increase in full-year guidance. The bank forecasts 2026 revenue of $63.3 billion and core earnings per share of $9.48, with a margi...
